Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development

Kosuke Dodo, Atsushi Aoyama, Tomomi Noguchi-Yachide, Makoto Makishima, Hiroyuki Miyachi, Yuichi Hashimoto

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Liver X receptors (LXR), which were originally reported as oxysterol-activated nuclear receptors, were recently found to recognize glucose as a physiological ligand. On this basis, we have already developed novel LXR antagonists based upon α-glucosidase inhibitors derived from thalidomide. Here, to clarify the relationship between α-glucosidase inhibition and LXR modulation, we investigate the α-glucosidase-inhibitory activity of typical LXR ligands and the LXR-modulating activity of typical α-glucosidase inhibitors. Although there were some exceptions, co-existence of LXR-regulatory and α-glucosidase-inhibitory activities seemed to be rather general among the examined compounds. The LXR ligands were found to be non-competitive α-glucosidase inhibitors, suggesting that it might be possible to separate the two activities. To test this idea, we focused on riccardin C, a naturally occurring LXR ligand, which we found here to be a potent α-glucosidase inhibitor as well. Structural development of riccardin C afforded novel LXR antagonists lacking α-glucosidase-inhibitory activity, 19c and 19f, and a LXRα-selective antagonist, 22.

Original languageEnglish
Pages (from-to)4272-4285
Number of pages14
JournalBioorganic and Medicinal Chemistry
Volume16
Issue number8
DOIs
Publication statusPublished - Apr 15 2008
Externally publishedYes

Fingerprint

Glucosidases
Liver
Ligands
Liver X Receptors
Thalidomide
Cytoplasmic and Nuclear Receptors
Modulation

Keywords

  • Antagonist
  • Glucosidase
  • Inhibitor
  • Liver X receptor
  • Structural development

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. / Dodo, Kosuke; Aoyama, Atsushi; Noguchi-Yachide, Tomomi; Makishima, Makoto; Miyachi, Hiroyuki; Hashimoto, Yuichi.

In: Bioorganic and Medicinal Chemistry, Vol. 16, No. 8, 15.04.2008, p. 4272-4285.

Research output: Contribution to journalArticle

Dodo, Kosuke ; Aoyama, Atsushi ; Noguchi-Yachide, Tomomi ; Makishima, Makoto ; Miyachi, Hiroyuki ; Hashimoto, Yuichi. / Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. In: Bioorganic and Medicinal Chemistry. 2008 ; Vol. 16, No. 8. pp. 4272-4285.
@article{7ad8386641fb46f79cfdfa683d51891b,
title = "Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development",
abstract = "Liver X receptors (LXR), which were originally reported as oxysterol-activated nuclear receptors, were recently found to recognize glucose as a physiological ligand. On this basis, we have already developed novel LXR antagonists based upon α-glucosidase inhibitors derived from thalidomide. Here, to clarify the relationship between α-glucosidase inhibition and LXR modulation, we investigate the α-glucosidase-inhibitory activity of typical LXR ligands and the LXR-modulating activity of typical α-glucosidase inhibitors. Although there were some exceptions, co-existence of LXR-regulatory and α-glucosidase-inhibitory activities seemed to be rather general among the examined compounds. The LXR ligands were found to be non-competitive α-glucosidase inhibitors, suggesting that it might be possible to separate the two activities. To test this idea, we focused on riccardin C, a naturally occurring LXR ligand, which we found here to be a potent α-glucosidase inhibitor as well. Structural development of riccardin C afforded novel LXR antagonists lacking α-glucosidase-inhibitory activity, 19c and 19f, and a LXRα-selective antagonist, 22.",
keywords = "Antagonist, Glucosidase, Inhibitor, Liver X receptor, Structural development",
author = "Kosuke Dodo and Atsushi Aoyama and Tomomi Noguchi-Yachide and Makoto Makishima and Hiroyuki Miyachi and Yuichi Hashimoto",
year = "2008",
month = "4",
day = "15",
doi = "10.1016/j.bmc.2008.02.078",
language = "English",
volume = "16",
pages = "4272--4285",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development

AU - Dodo, Kosuke

AU - Aoyama, Atsushi

AU - Noguchi-Yachide, Tomomi

AU - Makishima, Makoto

AU - Miyachi, Hiroyuki

AU - Hashimoto, Yuichi

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Liver X receptors (LXR), which were originally reported as oxysterol-activated nuclear receptors, were recently found to recognize glucose as a physiological ligand. On this basis, we have already developed novel LXR antagonists based upon α-glucosidase inhibitors derived from thalidomide. Here, to clarify the relationship between α-glucosidase inhibition and LXR modulation, we investigate the α-glucosidase-inhibitory activity of typical LXR ligands and the LXR-modulating activity of typical α-glucosidase inhibitors. Although there were some exceptions, co-existence of LXR-regulatory and α-glucosidase-inhibitory activities seemed to be rather general among the examined compounds. The LXR ligands were found to be non-competitive α-glucosidase inhibitors, suggesting that it might be possible to separate the two activities. To test this idea, we focused on riccardin C, a naturally occurring LXR ligand, which we found here to be a potent α-glucosidase inhibitor as well. Structural development of riccardin C afforded novel LXR antagonists lacking α-glucosidase-inhibitory activity, 19c and 19f, and a LXRα-selective antagonist, 22.

AB - Liver X receptors (LXR), which were originally reported as oxysterol-activated nuclear receptors, were recently found to recognize glucose as a physiological ligand. On this basis, we have already developed novel LXR antagonists based upon α-glucosidase inhibitors derived from thalidomide. Here, to clarify the relationship between α-glucosidase inhibition and LXR modulation, we investigate the α-glucosidase-inhibitory activity of typical LXR ligands and the LXR-modulating activity of typical α-glucosidase inhibitors. Although there were some exceptions, co-existence of LXR-regulatory and α-glucosidase-inhibitory activities seemed to be rather general among the examined compounds. The LXR ligands were found to be non-competitive α-glucosidase inhibitors, suggesting that it might be possible to separate the two activities. To test this idea, we focused on riccardin C, a naturally occurring LXR ligand, which we found here to be a potent α-glucosidase inhibitor as well. Structural development of riccardin C afforded novel LXR antagonists lacking α-glucosidase-inhibitory activity, 19c and 19f, and a LXRα-selective antagonist, 22.

KW - Antagonist

KW - Glucosidase

KW - Inhibitor

KW - Liver X receptor

KW - Structural development

UR - http://www.scopus.com/inward/record.url?scp=42149184935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149184935&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2008.02.078

DO - 10.1016/j.bmc.2008.02.078

M3 - Article

C2 - 18343126

AN - SCOPUS:42149184935

VL - 16

SP - 4272

EP - 4285

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 8

ER -